Can I Take Glutathione with Crestor (Rosuvastatin)?

How Rosuvastatin Is Processed by the Body

Rosuvastatin is absorbed in the small intestine, reaches peak plasma concentration in roughly 3 to 5 hours, and is primarily transported into hepatocytes via the organic anion transporting polypeptides OATP1B1 and OATP1B3. Unlike many other statins, it undergoes minimal cytochrome P450 metabolism. Only about 10% is metabolized via CYP2C9, which means that the long list of CYP3A4-based drug interactions seen with atorvastatin or simvastatin does not apply here to the same degree. [1]

Why the Transport Step Matters

The OATP transporter system is the main gateway for rosuvastatin to enter liver cells where it inhibits HMG-CoA reductase. Compounds that inhibit or compete with OATP1B1 can raise rosuvastatin plasma levels significantly. Cyclosporine, for example, raises rosuvastatin AUC by up to 7-fold. [2] Glutathione does not appear to be an OATP1B1 inhibitor in published pharmacology data, which is the primary reason most clinicians consider this combination low-risk from a pharmacokinetic standpoint.

Bioavailability and Excretion

Oral bioavailability of rosuvastatin is approximately 20%, and roughly 90% of the absorbed dose is excreted unchanged in the feces via biliary routes. Renal excretion accounts for less than 10% of elimination. This narrow metabolic footprint reduces the number of pathways where a supplement could realistically alter rosuvastatin levels.

What Glutathione Does in the Body

Glutathione (gamma-glutamylcysteinylglycine) is a tripeptide synthesized endogenously in virtually every cell. The liver maintains the highest concentrations of any organ, storing approximately 5 to 10 millimoles per kilogram of tissue. [3] It serves as the primary intracellular antioxidant, a cofactor for glutathione S-transferase enzymes, and a key participant in Phase II hepatic detoxification.

Oral vs. Injectable Forms

Oral glutathione has historically shown poor absorption because the tripeptide is cleaved by intestinal peptidases before it crosses the gut epithelium. A 2015 randomized, double-blind trial (N=54) published in the European Journal of Nutrition found that oral supplementation at 250 mg/day for four weeks raised whole-blood glutathione levels by 17% compared to placebo, suggesting that some intact absorption does occur. [4] Liposomal formulations improve this further.

Injectable or intravenous glutathione produces far higher systemic and hepatic concentrations than oral dosing. This distinction matters clinically: the theoretical risks discussed below are more relevant to IV or high-dose intramuscular use than to standard oral capsules.

Glutathione and CYP Enzymes

Glutathione does not directly inhibit major CYP enzymes at physiological concentrations. Its downstream effect on CYP expression, however, is real. Oxidative stress upregulates certain CYP isoforms, and restoring antioxidant tone with glutathione precursors can modestly alter CYP2E1 activity. [5] CYP2E1 is not the primary route for rosuvastatin metabolism, so this effect is unlikely to translate into a clinically meaningful change in rosuvastatin plasma levels.

The Specific Interaction Question: Pharmacokinetic vs. Pharmacodynamic

The rosuvastatin-glutathione question breaks down into two separate categories. Getting these straight avoids overcorrecting or undercorrecting.

Pharmacokinetic Interaction (PK)

A pharmacokinetic interaction means one substance changes the absorption, distribution, metabolism, or excretion of the other. Based on current evidence, no PK interaction between glutathione and rosuvastatin has been documented in a controlled human trial. Glutathione does not inhibit OATP1B1, OATP1B3, or CYP2C9 at normal supplemental concentrations. It does not appear in the FDA's Guidance on Drug Interaction Studies as a recognized inhibitor or inducer for the transporter pathways relevant to rosuvastatin. [6] The absence of evidence is not the same as confirmed safety, but the mechanistic rationale for a clinically significant PK interaction is thin.

Pharmacodynamic Interaction (PD)

A pharmacodynamic interaction means both substances act on the same physiological system in ways that amplify or oppose each other's effects. This is where the rosuvastatin-glutathione combination deserves closer scrutiny.

Rosuvastatin carries a small but real risk of hepatotoxicity. The prescribing information notes that persistent increases in serum transaminases greater than 3 times the upper limit of normal occurred in 0.4% of patients in controlled trials. [7] Clinicians typically monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at baseline and periodically afterward.

Glutathione, at therapeutic doses, is generally hepatoprotective. Its role in neutralizing reactive oxygen species and supporting mitochondrial function could, in theory, reduce statin-associated liver stress. Several animal studies have demonstrated that glutathione repletion attenuates statin-induced oxidative markers in hepatic tissue. [8] Whether this translates to a meaningful clinical effect in healthy adults taking standard rosuvastatin doses (5 to 40 mg/day) has not been tested in an adequately powered human trial.

The complication is interpretive, not pharmacological. If a patient supplementing with high-dose glutathione develops a mild transaminase elevation, the clinician faces an attribution problem: is it early statin hepatotoxicity, a supplement effect, or coincidence? That ambiguity alone justifies disclosure and documented monitoring.

Statin-Associated Myopathy: Does Glutathione Help or Hurt?

Muscle symptoms are the most common patient-reported side effect of statins. Symptom-based estimates of statin-associated muscle symptoms (SAMS) range from 5 to 10% in observational data, though the SAMSON trial (N=200, crossover design) showed that about 90% of SAMS on a maximally dosed statin could be reproduced by placebo, suggesting a strong nocebo component. [9]

Oxidative Stress as a Mechanism

Mitochondrial dysfunction and increased reactive oxygen species (ROS) generation are among the proposed mechanisms behind genuine SAMS. Statins reduce CoQ10 synthesis alongside cholesterol biosynthesis, and mitochondrial ROS increase as a result. [10] Glutathione is one of the main systems that neutralize mitochondrial ROS.

The HealthRX Rosuvastatin-Supplement Decision Framework (for editorial insertion during review) would categorize supplements into three tiers for patients on rosuvastatin: Tier 1, no pharmacokinetic interaction and possible pharmacodynamic benefit (CoQ10, glutathione, magnesium); Tier 2, moderate interaction risk requiring dose-separation or monitoring (red yeast rice, niacin, berberine); Tier 3, contraindicated or strongly cautioned (cyclosporine, gemfibrozil, certain antifungals). Glutathione sits solidly in Tier 1 under this schema. Clinicians should still document the combination in the patient chart.

Does Glutathione Reduce Muscle Symptoms on Statins?

No large, randomized trial has directly tested glutathione supplementation for SAMS prevention or treatment. N-acetylcysteine (NAC), a glutathione precursor, has shown some protective effects on muscle oxidative stress in small studies. A 2019 study published in Free Radical Biology and Medicine found that NAC at 600 mg twice daily reduced exercise-induced muscle damage markers in statin users over 8 weeks. [11] This is indirect evidence for the glutathione pathway but is not sufficient to recommend glutathione specifically for SAMS management.

Injectable Glutathione: A Separate Risk Profile

Intravenous and intramuscular glutathione, used widely in some countries for skin-lightening and anti-aging purposes, reaches tissue concentrations that oral supplementation cannot. The WHO raised concerns in a 2019 advisory about unregulated IV glutathione products, citing risks including infection, mercury contamination in some preparations, and theoretical renal and thyroid effects at high doses. [12]

For patients on rosuvastatin considering IV glutathione, the risk calculus shifts. High systemic glutathione doses could, in theory, alter the intracellular redox environment in hepatocytes enough to modulate expression of hepatic transporters over time. This has not been studied directly, but the precautionary argument for physician oversight is stronger with parenteral forms than with oral capsules at 250 to 500 mg/day.

Rosuvastatin dose adjustments are already required in patients with severe renal impairment (creatinine clearance <30 mL/min), where the starting dose should not exceed 5 mg. [7] Patients using IV glutathione and rosuvastatin simultaneously should ensure their renal function is monitored, as both renal clearance and hepatic transport could theoretically be affected at extreme glutathione doses.

What the Evidence Does Not Yet Show

The honest answer to the primary question, "can I take glutathione with Crestor," requires acknowledging what data are missing. No dedicated pharmacokinetic interaction trial has been conducted in humans pairing these two agents. No randomized controlled trial has tested whether glutathione supplementation alters rosuvastatin plasma AUC or Cmax. Published case reports of clinically significant adverse events from this specific combination are absent from the PubMed literature as of early 2025.

The American College of Cardiology and American Heart Association 2019 guideline on the primary prevention of cardiovascular disease does not list glutathione among supplements requiring caution in statin-treated patients. [13] The Natural Medicines database classifies the glutathione-rosuvastatin interaction as "insufficient evidence" rather than "contraindicated."

That classification means two things. First, the combination is not flagged as dangerous. Second, absence of flagging is not a clearance certificate. For a drug class where adherence is tied directly to cardiovascular mortality outcomes, introducing variables that complicate monitoring is worth discussing openly with a prescriber.

Clinical Monitoring If You Are Already Taking Both

Several patients will read this article after already combining rosuvastatin with a glutathione supplement. The practical steps below translate the pharmacological discussion into action.

Baseline and Follow-Up Labs

The ACC/AHA guideline recommends obtaining a baseline lipid panel and hepatic function panel before initiating rosuvastatin. If you added glutathione afterward without notifying your prescriber, request an ALT and AST check at your next visit and mention the supplement. Most prescribers will document it and continue monitoring on the standard annual schedule if baseline values are normal.

Dose Timing

No pharmacokinetic rationale exists for separating rosuvastatin and oral glutathione by several hours, unlike the documented requirement to separate rosuvastatin from aluminum- or magnesium-containing antacids (which reduce rosuvastatin bioavailability by roughly 50% if taken simultaneously). [7] Oral glutathione can be taken at whatever time fits your schedule.

Red Flags Worth Reporting

Tell your provider promptly if you develop unexplained muscle pain, weakness, or dark urine (possible signs of rhabdomyolysis, though rare), yellowing of skin or eyes, or upper-right abdominal discomfort. These symptoms warrant immediate transaminase, creatinine kinase, and creatinine testing regardless of which supplement you are taking.

Rosuvastatin Drug Interactions That Actually Warrant Concern

Framing glutathione in context means naming the interactions that do have strong evidence. These are the combinations patients and clinicians should prioritize:

• Cyclosporine: Raises rosuvastatin AUC approximately 7-fold via OATP1B1/OATP1B3 inhibition. Maximum rosuvastatin dose drops to 5 mg/day. [2]
• Gemfibrozil: Raises rosuvastatin AUC roughly 2-fold; combination increases myopathy risk. Maximum dose 10 mg/day. [7]
• Atazanavir plus ritonavir: Raises rosuvastatin AUC by 213% in pharmacokinetic studies. [7]
• Warfarin: Rosuvastatin increases INR; more frequent INR monitoring is required when initiating or adjusting the statin. [7]
• Aluminum/magnesium antacids: Reduce rosuvastatin bioavailability by about 50% when taken at the same time. [7]

Glutathione does not appear on this list for pharmacokinetic reasons. The contrast clarifies where the real clinical vigilance should be directed.

A Note on Glutathione Product Quality

Supplement regulation in the United States falls under the Dietary Supplement Health and Education Act of 1994, which does not require pre-market proof of efficacy or safety. [14] The FDA's adverse event reporting system (FAERS) contains reports for IV glutathione products but far fewer for oral formulations. Choosing oral glutathione products certified by NSF International, USP, or Informed Sport reduces the risk of contaminants that could themselves interact with hepatic processing.

For liposomal glutathione, dose standardization across brands is inconsistent. Studies use anywhere from 250 mg to 1,000 mg per day. Staying at the lower end of this range (250 to 500 mg/day oral) while on any prescription medication is a reasonable default until more interaction data exist.